Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.

Hallinen, Taru; Kivelä, Santtu; Soini, Erkki; Harjola, Veli-Pekka; Pesonen, Mari

Hallinen, Taru; Kivelä, Santtu; Soini, Erkki; Harjola, Veli-Pekka; Pesonen, Mari.

Afiliação

Hallinen T; ESiOR Oy, Kuopio, Finland.
Kivelä S; ESiOR Oy, Kuopio, Finland.
Soini E; ESiOR Oy, Kuopio, Finland.
Harjola VP; Emergency Medicine, University of Helsinki, Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.
Pesonen M; Boehringer Ingelheim Ky, Helsinki, Finland.

Clinicoecon Outcomes Res ; 15: 1-13, 2023.

Article em En | MEDLINE | ID: mdl-36636485

Palavras-chave

cost-utility analysis; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; sodium-glucose cotransporter 2 inhibitor

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Finlândia País de publicação: Nova Zelândia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google